Literature DB >> 19706751

Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.

Antonella Federico1, Pierlorenzo Pallante, Mimma Bianco, Angelo Ferraro, Francesco Esposito, Maria Monti, Marianna Cozzolino, Simona Keller, Monica Fedele, Vincenza Leone, Giancarlo Troncone, Lorenzo Chiariotti, Piero Pucci, Alfredo Fusco.   

Abstract

Chromobox protein homologue 7 (CBX7) is a chromobox family protein encoding a novel polycomb protein, the expression of which shows a progressive reduction, well related with the malignant grade of the thyroid neoplasias. Indeed, CBX7 protein levels decreased in an increasing percentage of cases going from benign adenomas to papillary, follicular, and anaplastic thyroid carcinomas. To elucidate the function of CBX7 in carcinogenesis, we searched for CBX7 interacting proteins by a proteomic analysis. By this approach, we identified several proteins. Among these proteins, we selected histone deacetylase 2 (HDAC2), which is well known to play a key role in neoplastic cell transformation and down-regulation of E-cadherin expression, the loss of which is a critical event in the epithelial-to-mesenchymal transition. We confirmed by coimmunoprecipitation that CBX7 physically interacts with the HDAC2 protein and is able to inhibit its activity. Then, we showed that both these proteins bind the E-cadherin promoter and that CBX7 up-regulates E-cadherin expression. Consistent with these data, we found a positive statistical correlation between CBX7 and E-cadherin expression in human thyroid carcinomas. Finally, we showed that the expression of CBX7 increases the acetylation status of the histones H3 and H4 on the E-cadherin promoter. Therefore, the ability of CBX7 to positively regulate E-cadherin expression by interacting with HDAC2 and inhibiting its activity on the E-cadherin promoter would account for the correlation between the loss of CBX7 expression and a highly malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706751     DOI: 10.1158/0008-5472.CAN-09-1542

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Polycomb protein family member CBX7 plays a critical role in cancer progression.

Authors:  Pierlorenzo Pallante; Floriana Forzati; Antonella Federico; Claudio Arra; Alfredo Fusco
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

3.  CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas).

Authors:  Mario Monaco; Gennaro Chiappetta; Concetta Aiello; Antonella Federico; Romina Sepe; Daniela Russo; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Eur Thyroid J       Date:  2014-10-15

Review 4.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 5.  Context-dependent actions of Polycomb repressors in cancer.

Authors:  M Koppens; M van Lohuizen
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

6.  Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein.

Authors:  Gelsomina Mansueto; Floriana Forzati; Angelo Ferraro; Pierlorenzo Pallante; Mimma Bianco; Francesco Esposito; Antonino Iaccarino; Giancarlo Troncone; Alfredo Fusco
Journal:  Genes Cancer       Date:  2010-03

Review 7.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

Review 8.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

9.  CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.

Authors:  Zhengnan Huang; Yilin Yan; Zhen Zhu; Jiakuan Liu; Xiao He; Sumiya Dalangood; Meiqian Li; Mingyue Tan; Jinming Cai; Pengfei Tang; Ruimin Huang; Bing Shen; Jun Yan
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

10.  Mitogen-activated protein kinase signaling mediates phosphorylation of polycomb ortholog Cbx7.

Authors:  Hsan-au Wu; Jeremy L Balsbaugh; Hollie Chandler; Athena Georgilis; Hayley Zullow; Jeffrey Shabanowitz; Donald F Hunt; Jesus Gil; Gordon Peters; Emily Bernstein
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.